David Reddy readied for top IFPMA job

6 November 2023

Thomas Cueni, the director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and secretary of the Biopharmaceutical CEO Roundtable (BCR), is set to retire in April 2024.

The IFPMA is the international industry trade body that leads in official relations with the World Health Organization and other United Nations bodies representing more than 90 companies and associations around the world.

Replacing Mr Cueni, a former journalist and Swiss diplomat who has led the IFPMA since February 2017, will be David Reddy, the current chief executive of Medicines for Malaria Ventures (MMV) and former executive at Swiss pharma giant Roche (ROG: SIX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK